Prediction of Risk of Calcification of Heart Valve Bioprostheses on the Basis of Comprehensive Assessment of Recipients Clinical Factors and Their Compliance With Therapy

Purpose. The development of the prediction methods of calcification risk of heart valve bioprostheses (BP) based on comprehensive assessment of the impact of clinical factors of the recipients and their adherence to medication. Materials and methods. We performed a retrospective study of clinical status and adherence to drug therapy of 170 recipients of heart valve BP with (n=63) and without (n=109) calcification. We used the method of comprehensive assessment of the analyzed parameters with estimation of prognostic coefficients for each of them, followed by calculation of integral indicators and construction on their basis of prognostic models for the various intervals of BP functioning. Results. The most important risk factors of calcium-associated BP dysfunctions at any duration of observation were heart failure decompensation, as well as the discontinuation of ACE inhibitors and β-blockers. At duration of BP functioning up to four years negative effect on prognosis produced the presence of concomitant multifocal atherosclerosis, during additional 4 (from 4 to 8) years -diabetes mellitus, and afterwards (over 8 years) - coronary artery disease. Lowering of probability of BP calcium degeneration was related to regular use of aldosterone antagonists during first 4 years after BP implantation and regular subsequent use of statins. Conclusions. Based on the comprehensive assessment of clinical status of patients and their compliance to medication it is possible to make adequate prediction models for assessment of the risk of structural dysfunctions due to BP calcification at various time intervals of remote postoperative period.

кальцификация, биопротезы, клинический статус, приверженность к терапии, calcification, bioprostheses, clinical status, compliance

1. Oakley R., Kleine P., Bach D. S. Choice of Prosthetic Heart Valve in Today's Practice. Circulation 2008; 117 (2):253-256. DOI:10.1161 /CIRCULATIONAHA. 107.736819.

2. Pibarot P., Dumesnil J. Prosthetic Heart Valves: Selection of the Optimal Prosthesis and Long-Term Management. Circulation 2009;119 (7):1034-1048. DOI: 10.1161/CIRCULATIONAHA. 108.778886.

3. Tillquist M., Maddox T. Cardiac crossroads: deciding between mechanical or bioprosthetic heart valve replacement. Patient Prefer Adherence 2011;5:91-99. DOI: 10.2147/PPA. S16420.

4. Barbarash O. L., Rutkovskaya N. V., Hryachkova O. N. et al. Impact of recipient-related factors on structural dysfunction rates of xenoaorticbioprothetic heart valve. Patient Preference and Adherence 2015;9:389-399. DOI: 10.2147/PPA. S76001.

5. Schoen F.J., Levy R.J. Calcification of tissue heart valve substitutes: progress toward understanding and prevention. Ann Thoracic Surgery 2005;79:1072-1080.

6. New S. E. P., Aikawa E. Molecular imaging insights into early inflammatory stages of arterial and aortic valve calcification. Circulation Research 2011;108:1381-1391. DOI: 10.1161 /CIRCRESAHA. 110.234146.

7. Briand M., Pibarot P., Despres J. P. et al. Metabolic syndrome is associated with faster degeneration of bioprosthetic valves. Circulation 2006;114:1512-1517.

8. Lorusso R., Gelsomino S., Luca F. et al. Type 2 diabetes mellitus is associated with faster degeneration of bioprosthetic valve: results from a propensity score-matched italian multicenter study. Circulation 2012;125:604-614. DOI: 10.1161/ CIRCULATIONAHA. 111.025064. Epub 2011 Dec 27.

9. Mahjoub Y., Mathieu P., Senechal M. et al. ApoB/ApoA ratio is associated with increased risk bioprosthetic valve degeneration. Journal of the American College of Cardiology 2013;61:752-761. DOI: 10.1016/j. jacc. 2012.11.033.

10. Antonii-Canterin F., Zuppiroli A., Baldessin F. et al. Is there a role of statins in the prevention of aortic biological prostheses degeneration. Cardiovascular Ultrasound 2006;4:26.

11. Gkizas S., Koumoundourou D., Sirinian X. et al. Aldosterone receptor blockade inhibits degenerative processes in the early stage of calcific aortic stenosis. Eur J. Pharmacol 2010:235;311-316. DOI: 10.1016/j.ejphar. 2010.05.048.

12. Holme I., Boman K., Brudi P. et al. Observed and predictedreduction of ischemic cardiovascular events in the simvastatin and ezeti mibe in aortic stenosis trial. Am J. Cardiol 2010;105:1802-1808. DOI: 10.1016/j.amjcard. 2010.01.363.

13. Aronow W. S. Osteoporosis, osteopenia, and atherosclerotic vascular disease. Arch Med Scie 2011;7:21-26. DOI: 10.5114/aoms. 2011.20599.

14. Miller J. D., Weiss R. M., Heistad D. D. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011;108:1392-1412. DOI: 10.1161/CIRCRESAHA. 110.234138.

15. Wylie-Sears J., Aikawa E., Levine R. A. et al. Mitral valve endothelial cells with osteogenic differentiation potential. Arteriosclerosis, Thrombosis and Vascular Biology 2011;31:598-607. DOI: 10.1161/ ATVBAHA. 110.216184.

16. Ruiz J. L., Hutcheson J. D., Aikawa E. Cardiovascular calcification: Current controversies and novel concepts. Cardiovasc Pathol 2015;24 (4):207-212. DOI: 10.1016/j.carpath. 2015.03.002.

17. Kuan Y. H., Dasi L. P., Yoganathan A. P. Recent advances in polymeric heart valves research. Int J. Biomat Res Eng (IJBRE) 2011;1 (1):1-17.

18. Min B.J., Kim Y.J., Choi J. W. et al. Histologic Characteristics and Mechanical Properties of Bovine Pericardium Treated with Decellularization and α-Galactosidase: A Comparative Study. KoreanJ Thorac Cardiovasc Surg 2012;45:368-379. DOI: 10.5090/ kjtcs. 2012.45.6.368.

19. Evrard S., Delanaye P., Kamel S. et al. Vascular calcification: from pathophysiology to biomarkers. Clinica Chimica Acta 2015;438:401-414. DOI: 10.1016/j.cca. 2014.08.034.

20. Cote C., Pibarot P., Despres J. P. et al. Association between circulating oxidized low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008;94:1175-1180.

21. Gilmanov D., Bevilacqua S., Mazzone A., Glauber M. Do statins slow the process of calcification of aortic tissue valves? Interact Cardiovasc Thorac Surg 2010;11 (3):297-301. DOI: 10.1510/icvts. 2009.230920.

22. Schurgers L.J., Spronk H. M., Soute B. A. et al. Regression of warfarin-induced medial elastocalcinosis by high intake of vitamin K. in rats. Blood 2007;109:2823-2831.

23. Schurgers L.J., Uitto J., Reutelingsperger C. P. Vitamin K-dependent carboxylation of matrix Gla-protein: a crucial switch to control ectopic mineralization. Trends Mol Med 2013;19:217-226. DOI: 10.1016/j.molmed. 2012.12.008.